Immunotherapy is weaponizing the body's immune system against cancer or other disease. One of the most promising approaches is CAR-T cell therapy, yet as this technology has been implemented, it's limitations have been identified. Dr. Andy Scharenberg described the current drawbacks of CAR-T cells and how his company, Umoja, is re-engineering CAR-T cells in vivo to create more effective therapies, including approaches that can address solid tumors. Co-hosted by Donald Coon.
www.umoja-biopharma.com
Fler avsnitt av Talking Biotech with Dr. Kevin Folta
Visa alla avsnitt av Talking Biotech with Dr. Kevin FoltaTalking Biotech with Dr. Kevin Folta med Kevin Folta finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.
